IP Library Granted Patent US 7,615,616
Granted Patent B2
US 7,615,616 · App. 10/661,809 · Granted Nov 10, 2009

Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby

Assignees: The Texas A&M University System; Inhibitex, Inc.; The UAB Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,616
App. No.
10/661,809
Granted
Nov 10, 2009
Kind
B2
Abstract

A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®—like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.

Claims (10)

1. An isolated antibody capable of binding to an amino acid sequence consisting of amino acids 33-592 of SEQ ID NO: 13.

2. The antibody according to claim 1 wherein the antibody is a monoclonal antibody.

3. The antibody according to claim 1 selected from the group consisting of single chain, chimeric, murine, humanized and human monoclonal antibodies.

4. The antibody according to claim 1 , wherein said antibody treats an E. faecalis bacterial infection in a human or animal.

5. The antibody according to claim 1 , wherein said antibody is suitable for parenteral, oral, intranasal, subcutaneous, aerosolized or intravenous administration in a human or animal.

6. Isolated antisera containing an antibody according to claim 1 .

7. A diagnostic kit comprising an antibody according to claim 1 and means for detecting binding by that antibody.

8. A diagnostic kit according to claim 7 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.

9. A pharmaceutical composition comprising an effective amount of the antibody of claim 1 and a pharmaceutically acceptable vehicle, carrier or excipient.

10. The antibody according to claim 1 , wherein the antibody is a polyclonal antibody.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 23, 2018
From: TEXAS A&M UNIVERSITY SYSTEM
To: NIH - DEITR
Reel/Frame 044703/0743 →
CONFIRMATORY LICENSE Recorded Jun 2, 2011
From: TEXAS A&M UNIVERSITY SYSTEM
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026381/0302 →
CONFIRMATORY LICENSE Recorded Apr 18, 2008
From: THE TEXAS A&M UNIVERSITY SYSTEM
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020826/0672 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2004
From: HOOK, MAGNUS; XU, YI; SILLANPAA, JOUKO; BOWDEN, MARIA; PATTI, JOSEPH M.; HUTCHINS, JEFF T.; HALL, ANDREA; STHANAM, NARAYANA; PONNURAJ, KARTHE
To: TEXAS A&M UNIVERSITY SYSTEM, THE; INHIBITEX, INC.; UAB RESEARCH FOUNDATION, THE
Reel/Frame 014916/0243 →
Continuity (2)
Provisional Application 6041030300 · Sep 13, 2002
Related Publication 20040101919A1 · May 27, 2004